<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218695</url>
  </required_header>
  <id_info>
    <org_study_id>BIDMC-ABX-pilot-19</org_study_id>
    <nct_id>NCT04218695</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics in Admitted Cirrhotics</brief_title>
  <official_title>A Pilot Study of the Effect of Prophylactic Antibiotics on Hospitalized Patients With Advanced Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Association for the Study of Liver Diseases Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study, the investigators aim to assess feasibility of subject identification
      and data collection, including specimen processing, as well as the rate of enrollment for a
      future, larger study of the effect of empiric antibiotics for all patients with advanced
      cirrhosis admitted to the hospital without an existing indication for new antibiotic use.
      Specifically, the investigators will assess the incidence of infection after the time of
      enrollment and associated outcomes. Subjects will be randomly assigned to receive antibiotics
      vs placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhosis is associated with a state of immune-compromise and progressive decompensation,
      acute on chronic liver failure (ACLF), and death are often caused by bacterial infections.
      Different sub-groups of patients with cirrhosis at increased risk, i.e. active upper
      gastrointestinal hemorrhage, low protein ascites, history of spontaneous bacterial
      peritonitis (SBP), are known to benefit from prophylactic antibiotics. The investigators
      hypothesize that hospitalized patients with advanced cirrhosis are also at increased risk and
      thus may benefit from preventive treatment. Subjects will be randomly assigned to receive an
      antibiotic vs placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded placebo-controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Infections</measure>
    <time_frame>For 7 days or until end of hospital stay</time_frame>
    <description>Incident bacterial infection after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Days in hospital after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>In-hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>Up to 30-days</time_frame>
    <description>Includes f/u after discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incident C difficile colitis</measure>
    <time_frame>30 days</time_frame>
    <description>Positive stool toxin/PCR with new onset diarrhea</description>
  </other_outcome>
  <other_outcome>
    <measure>Incident ACLF</measure>
    <time_frame>During hospital admission up to 30 days</time_frame>
    <description>(by NACSELD) or change in CLIF-C ACLF score</description>
  </other_outcome>
  <other_outcome>
    <measure>Incident variceal hemorrhage</measure>
    <time_frame>During hospital admission up to 30 days</time_frame>
    <description>Incident variceal hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Increase in MELD-Na</measure>
    <time_frame>Upon discharge (or at 30 days)</time_frame>
    <description>&gt;2 pts</description>
  </other_outcome>
  <other_outcome>
    <measure>Fungal infection</measure>
    <time_frame>During hospital admission up to 30 days</time_frame>
    <description>Incident fungal infection (by culture data or requirement for new anti-fungal medication)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers of infection</measure>
    <time_frame>Once at time of randomization</time_frame>
    <description>Procalcitonin and C-reactive protein</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (50cc) once daily for up to one week or until end of hospitalization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rocephin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>50cc intravenous once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MELD-Na &gt;= 18

          -  Cirrhosis as defined by liver biopsy or a composite assessment of available results
             from imaging, elastography, prior records, and laboratory studies

        Exclusion Criteria:

          -  Inability to obtain consent (from subject or next of kin/legal authorized
             representative (LAR)

          -  Allergy to cephalosporins

          -  Pregnancy (due to limited prospective data regarding safety of ceftriaxone)

          -  Existing indication for new antibiotics, e.g. upper gastrointestinal hemorrhage or
             apparent infection

          -  Use of major immunosuppressive medications (e.g. prednisone 20 mg/day or greater,
             immunosuppression for solid organ transplant)

          -  H/o recurrent C difficile infection within the past year (&gt;2) or requiring fecal
             microbiota transplant (FMT)

          -  Enrollment in the study protocol during a previous admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary P Fricker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Zachary Fricker, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Zachary Fricker</investigator_full_name>
    <investigator_title>Instructor, Division of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

